NRX Pharmaceuticals, Inc. SEC filings NRXP
NRX Pharmaceuticals, Inc. has 477 filings in SEC EDGAR's recent list, going back to Oct 13, 2017. Its latest annual report, Form 10-K, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Feb 24, 2026 | — |
| DEF 14A | Proxy statement | Feb 23, 2026 | Mar 23, 2026 |
| PRE 14A | Preliminary proxy statement | Feb 13, 2026 | Mar 23, 2026 |
| DEF 14A | Proxy statement | Sep 5, 2024 | Oct 8, 2024 |
| PRE 14A | Preliminary proxy statement | Aug 27, 2024 | Oct 8, 2024 |
| DEFA14A | Additional proxy material | Mar 20, 2024 | — |
| DEFA14A | Additional proxy material | Mar 18, 2024 | — |
| DEFA14A | Additional proxy material | Mar 13, 2024 | — |
| DEF 14A | Proxy statement | Mar 11, 2024 | Mar 21, 2024 |
| PRE 14A | Preliminary proxy statement | Dec 29, 2023 | Dec 29, 2023 |
| DEF 14A | Proxy statement | Nov 22, 2023 | Dec 19, 2023 |
| DEF 14A | Proxy statement | Jan 10, 2023 | Feb 2, 2023 |
| PRE 14A | Preliminary proxy statement | Dec 23, 2022 | Feb 2, 2023 |
| DEF 14A | Proxy statement | Jun 21, 2022 | Jul 18, 2022 |
| DEFA14A | Additional proxy material | Jun 16, 2022 | — |
| DEFA14A | Additional proxy material | Apr 8, 2021 | — |
| DEF 14A | Proxy statement | Apr 1, 2021 | Apr 21, 2021 |
| PRE 14A | Preliminary proxy statement | Mar 22, 2021 | Mar 19, 2021 |
| DEFA14A | Additional proxy material | Dec 15, 2020 | — |
| DEF 14A | Proxy statement | Dec 7, 2020 | Dec 18, 2020 |
| PRE 14A | Preliminary proxy statement | Nov 25, 2020 | Dec 18, 2020 |
| DEF 14A | Proxy statement | Jul 10, 2020 | Jul 23, 2020 |
| PRE 14A | Preliminary proxy statement | Jun 29, 2020 | Jul 23, 2020 |
| DEF 14A | Proxy statement | Mar 9, 2020 | Mar 23, 2020 |
| PRE 14A | Preliminary proxy statement | Feb 27, 2020 | Mar 23, 2020 |
| DEF 14A | Proxy statement | Nov 8, 2019 | Nov 21, 2019 |
| PRE 14A | Preliminary proxy statement | Oct 29, 2019 | Nov 21, 2019 |
| DEF 14A | Proxy statement | Aug 9, 2019 | Aug 21, 2019 |
| PRE 14A | Preliminary proxy statement | Jul 30, 2019 | Jul 30, 2019 |
| DEF 14A | Proxy statement | May 7, 2019 | May 21, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 26, 2019 | Apr 26, 2019 |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NRXP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Wilmington, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1719406
- Former names
- Big Rock Partners Acquisition Corp. (until May 24, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.